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Summary 
Antigen-specific CD4 + T cells play an important role in the allergic immune response to house 
dust mite (HDM) allergens in humans. The group 1 allergen ofDermatophagoides  spp. is a major 
target antigen in both B and T cell recognition of HDM. In vitro studies have shown that the 
presentation of peptides to human T  cells under appropriate conditions may lead to a state of 
specific nonresponsiveness.  Therefore, to determine ifpeptides are able to modulate the function 
of allergen-reactive  T cells in vivo, we have used a murine model of T  cell recognition of the 
HDM allergen Der p 1. The results demonstrate that inhalation of low concentrations ofpeptide 
containing the major T  cell epitope of Der p  1 (residues  111-139), induces tolerance in naive 
C57BL/6J mice such that they become profoundly unresponsive to an immunogenic challenge 
with the intact allergen.  When restimuhted in vitro with antigen, lymph node T calls isolated 
from tolerant mice secrete very low levels of interleukin 2, proliferate  poorly, and are unable 
to provide cognate help to stimulate specific antibody production. Furthermore, intranasal peptide 
therapy was able to inhibit an ongoing immune response to the allergen in mice and this has 
potential implications in the development of allergen-based  immunotherapy. 
,•proximately 
10% of the population suffers from allergy 
to  house dust  mite (HDM)  and CD4 +  T  cells are 
known to play an important role in allergic sensitization (1). 
In  vitro  studies  have  shown  that  human HDM-reactive 
CD4 + T  cell clones  can be rendered unresponsive by ex- 
posure to either high doses of their specific peptide epitope 
or to superantigens (2-6). Therefore, by modulating the func- 
tion of allergen-reactive  T  cells in vivo it may be possible 
to control an established allergic immune response in humans. 
Independent studies have shown that immunogenic  peptides 
can preferentially induce antigen-specific  T cell tolerance in 
naive mice when administered either intraperitoneally in IFA 
or intravenously (7-9). Experimental animals may also be ren- 
dered immunologically tolerant by feeding or inhaling an- 
tigens, and this state of nonresponsiveness is usually long- 
lasting and antigen spedfic (10-13). Experimental allergic ence- 
phalomyelitis (EAE) is a demyelinating autoimmune disease 
of rodents, and CD4 + T cells specific for myelin basic pro- 
tein (MBP)  are responsible for the development of disease. 
Pats can be protected from developing EAE by oral adminis- 
tration of MBP before an encephalitogenic challenge from 
the autoantigen (14, 15). Similarly, susceptible H2  u mice can 
be protected from developing EAE by inhalation but not oral 
administration of a peptide containing the immunodominant 
T  cell epitope on MBP (Ac 1-9,  1-11) (16). In a previous 
study, we have shown, using a routine model, that T  cell 
responses to the Der p 1 allergen  were inhibited by feeding 
recombinant peptides containing either major or minor T 
cell epitopes (Hoyne, G. F., M. G. Callow, M.-C. Kuo, and 
W. R. Thomas, manuscript submitted for publication). The 
induction of tolerance resulted in decreased responses in LN 
T cells to the whole antigen in vitro, and a loss of reactivity 
to all T  cell epitopes on the antigen was observed. 
In this study, we show that if naive C57BL/6J  mice inhale 
small quantities of synthetic peptides containing T cell epi- 
topes, they become profoundly unresponsive to a powerful 
immunogenic challenge with the allergen. LN T cells from 
tolerized mice secrete low levels of IL-2 and proliferate poorly 
when restimulated with antigen. They are also unable to pro- 
vide help for antibody production in vitro. Furthermore, in- 
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that had been previously sensitized to the Der p 1 allergen. 
These studies indicate that administering immunogenic pep- 
tides intranasally may be an effective way to control aberrant 
immune responses  that give rise to specific disease states in 
humans. 
Materials and Methods 
Animals.  Inbred C57BL/6J mice were purchased from the An- 
imal Resource Centre (Murdoch, Western Australia) at 6-8 wk 
of age and were kept under specific pathogen-frec conditions. 
Antigens.  The house dust mite allergen Der p 1 was affinity 
purified from spent mite medium (17). Synthetic peptides derived 
from the Der p 1 sequence  were synthesized using standard F-moc 
chemistry, peptides were purified by reverse-phase HPLC, and the 
sequence of individual  peptides were confirmed  by sequencing. The 
peptides used in this study were pl 111-139, pl  156-168 of the 
group 1 allergen of Derraatophagoides pteronyssinus (Der p 1) and 
p2 21-35 from the group 2 allergen (Der p 2). 
Preparation of Recombinant Proteins.  A cDNA insert encoding 
the 57-D0 fragment of the Der p I protein was ligated to the pGEX 
vector which expresses the fusion proteins with glutathione-S- 
transferase in Escherichia coil (18). The procedures for the cloning 
and expression of the fragments have  been described  (19). Log phase 
E. coli cells transformed with the pGEX-based construct were in- 
duced to express the  recombinant protein by adding 0.1  mM 
isopropylthiogalactosidase (Promega Corp., Madison, WI). The 
fusion protein was purified to homogeneity using glutathione- 
coupled agarose (Sigma Chemical Co., St. Louis, MO) following 
the techniques previously described by Smith and Johnson (18), 
and eventually lyophilized. 
Induction oflntranasal Tolerance.  Mice  were lightly anesthetized 
under ether and peptides dissolved in PBS were administered in- 
tranasally in a total volume of 10 gl using a micropipette on three 
consecutive  days. Mice were immunized subcutaneously  at the base 
of tail 7 d after the last treatment with 100 gg older p 1 emulsified 
in CFA (Difeo, Detroit,  MI) in a volume of 0.2 ml. To inhibit 
ongoing responses, mice were immunized intraperitoneally with 
Der p 1 in CFA, and 10 d later received 100/~g of pl 111-139 in- 
tranasally on five consecutive days. Mice were then reimmunized 
7 d later with 100/~g of Der p 1 in IFA (Difco) subcutaneously 
at the base of tail. 
Culture Medium.  LN cells  were  cultured in DME (GIBCO BRL, 
Gaithersburg, MD) supplemented  with 2% FCS (Commonwealth 
Serum Laboratories [CSL], Parkville, Victoria, Australia), 50 gM 
2-ME (Sigma Chemical Co.), 2 mM t-glutamine (CSL), and 20 
gg/ml gentamycin (David Bull Laboratories, Mulgrave, Victoria, 
Australia). CTLb2 cells were maintained in RPMI (GIBCO BRL) 
plus 10% FCS. 
T Cell Assays.  The periaortic and inguinal LNs were expressed 
through a stainless  steel wire mesh, washed, and cultured at 4  x 
10  s cells in a volume of 0.2 rnl in culture medium in a 96-well flat- 
bottom tissue culture plate (Becton Dickinson Labware, Lincoln 
Park, NJ). Protein or peptide antigens were added at various con- 
centrations and the cells were incubated at 37~  for 24 h. Super- 
natants were collected and stored at -20~  until required for the 
assay. 
Lymphokine Assays.  The CTLb2 cell  line proliferates  maximally 
with Ib2 but only poorly in the presence of IL-4 (20). 5  x  103 
CTLD2 ceils per well were cultured in supernatants for 24 h at 
37~  and pulsed with 1 gCi of [aH]thymidine. Cells were har- 
vested onto glass fiber filters and the proliferation determined by 
incorporation of [3H]thymidine  which was assessed using a direct 
beta counter (Packard Matrix 9600; Packard Instruments, Meriden, 
CT). 
In Vitro Antibody Production.  Mice  were immunized with 100 
gg of Der p 1 in CFA and 10 d later, the spleens of two mice were 
pooled and RBCs were lysed with sterile distilled water. Periaortic 
and inguinal LN cells were isolated 7 d after immunization from 
mice that had been treated on three consecutive days with either 
PBS (control) or pl 111-139 (tolerant) intranasally and immunized 
subcutaneously 7 d later with Der p 1/CFA. 2  x  106 spleen or 
LN ceils  were cultured alone in the presence ofDer p 1 in a volume 
of I ml culture medium in a 24-wall tissue culture plate. Alterna- 
tively, 106 spleen ceils were mixed with 106 LN cells from con- 
trol or tolerant mice and cultured in a 1-ml volume with the addi- 
tion  of antigen.  Cells were cultured for 7 d at 37~  and the 
supernatants were assayed  for the presence of Der p 1-specific Abs 
using an ELISA. 
ELISA.  Affnity-purified protein was diluted in 50 mM Na 
HCO3 buffer, pH 9.6, and coated onto an ELISA plate at  100 
gg/ml in a volume of 50 gl/weil. The plate was incubated over- 
night at 4~  and the next day was washed three times with PBS 
plus 0.05% Tween 20. Nonspecific  binding sites were blocked by 
incubating the plate with a solution of PBS containing 1% BSA 
for I h at room temperature. After three washes, serum was added 
to the plate at appropriate dilutions and incubated for 2 h at room 
temperature. The plate was washed as described and a 1/1,000 di- 
lution of goat anti-mouse Ig conjugated to horseradish  peroxidase 
was added and incubated for I h at room temperature. After a final 
wash, the color was developed  with AgIS containing 1% hydrogen 
peroxide for 20 min at room temperature. The reaction was stopped 
by addition of 0.1 M citric acid plus 0.01% sodium azide, and the 
OD of the plate was measured at 405 nm using an ELISA plate 
reader. Results are expressed as ELISA OD units. 
Results and Discussion 
C57BL/6J mice are high responders to the HDM allergen 
Der p 1 and T  cells recognize three different epitopes that 
are located within the following sequences: 110-131, 78-100, 
and 21--49 (Hoyne, G. F., et al.,  manuscript submitted for 
publication).  The  ability  of  purified  recombinant  GEX 
p57-130  and  a  synthetic peptide  that  contains  the  im- 
munodominant determinant, pl 111-139 to induce tolerance 
when administered intranasaUy were compared. This epitope 
was chosen for study because it represents a major T cell epi- 
tope recognized by human Der p 1-specific T cell dories (6). 
Mice received 100 gg of either peptide or PBS intranasally 
on three consecutive days and 1 wk later, all mice were chal- 
lenged with Der p 1 in CFA. LN cells draining the site of 
injection were collected 7 d later and stimulated in vitro with 
either protein or peptide for 24 h and the supernatants were 
assayed for IL-2. LN cells from mice treated with either pl 
111-139 or GEX p57-130 failed to respond with either Der 
p 1 (Fig.  1 A) or the T cell epitopes pl 111-139, pl 78-100 
and pl 21-49 (Fig. 1, B-D). Control mice that received PBS 
intranasally developed strong IL-2 responses to both the in- 
tact protein and the peptides (Fig.  1). 
In addition, mice received either PBS or pl  111-139 in- 
tranasally and 1 wk later were challenged subcutaneously with 
an immunogenic concentration of pl 111-139. LN cells were 
cultured in vitro with pl 111-139 and IL-2 secretion and T 
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Peptides given  intranasally  to mice  can inhibit  T cell  responses. 
Mice were treated with either PBS (/-/), 100 #g of GEX p57-130 (A), 
or pl 111-139 (0) intranasally  on three consecutive  days  and 1 wk later 
all mice were immunized  with 100/~g of Der p 1/CFA. LN cells were 
collected 7 d later and cultured in vitro with (A) Der p 1 protein, (/3) 
pl 111-139, (C) p1 78-100, or (D) pl 21--49 for 24 h. Data shows the 
mean IL-2 response of five mice per group •  SD. 
cell proliferation were determined. LN cells from control mice 
proliferated strongly to the peptide in vitro and produced 
IL-2 in a dose-dependent manner. However, T  cells from 
peptide-treated  mice proliferated only poorly and secreted only 
very low levels of IL-2 when rechallenged with the peptide 
in vitro (data not shown). Thus the induction of tolerance 
results in a state of nonresponsiveness to the whole antigen 
as a result of the failure of antigen-specific T cells to secrete 
IL-2 and to proliferate when restimulated. Tolerance to the 
immunodominant epitope also downregulated the response 
ofT cells directed to other epitopes on the antigen. Recently 
it has been reported that susceptible  H2  u mice are protected 
from developing EAE by inhalation of a synthetic peptide 
containing the immunodominant epitope MBP Ac 1-9 or 
Ac 1-11 before encephalitogenic challenge with MBP or pep- 
tide (16). In this study (16), the authors also observed that 
after the induction of tolerance to Ac 1-9 T  cell responses 
to subdominant epitopes on MBP were equally  downregulated. 
To determine the concentration of peptide required to in- 
duce peripheral tolerance, mice were treated intranasally on 
three consecutive days with either PBS or 1,  10, or 100/zg 
of pl  111-139 and then challenged 1 wk later with Der p 
1 in CFA. LN cells were collected 7 d after immunization 
and cultured in vitro with either Der p 1 or pl 111-139. T 
cell responses from each of the test groups after in vitro stim- 
ulation with Der p  1 or pl  111-139 were markedly down- 
regulated (Table 1), whereas T cells from control mice secreted 
large amounts of IL-2 when stimulated in vitro with either 
Der p 1 or peptide (Table 1). The immunodominant peptide 
at concentrations as low as 3  x  1 #g induced peripheral toler- 
ance when given intranasally. It is interesting to note that 
inhalation of similar levels of an intact protein in mice can 
induce immunological tolerance (12). Therefore mucosa of 
the respiratory tract appears to provide a highly efficient route 
for the induction of tolerance. 
Mice tolerized with pl 111-139 also failed to produce specific 
Abs. To demonstrate this, spleen cells collected from Der p 
1 immune mice were cultured in vitro either alone or with 
LN ceils from mice that had been treated intranasally with 
PBS or pl 111-139 and immunized subcutaneously with Der 
p  1 in CFA. Lymphocytes from both the test and control 
groups were cultured with Der p 1 for 7 d and the presence 
of anti-Der p 1 Abs in the culture supernatants were exam- 
ined by ELISA. Der p 1-specific Abs were present in the su- 
pernatants of both immune spleen cells and LN cells from 
PBS-treated  mice, but no Abs were detected in the superna- 
Table  1.  Intranasal Tolerance Induced with Microgram Quantities of Peptide 
Intranasal dose of antigen 
PBS  3  x  1fig  3  x  10fig  3  x  100ttg 
In vitro 
antigen 
Der p 1  5,075 (+  1,354)  890 (+  314)  1,088 (_+  391)  827 (_+  321) 
(40/~g/ml) 
pl  111-139  10,698 (_+ 3,477)  1,671 (,+ 692)  999 (_+ 643)  773 (.+ 537) 
(100/~g/ml) 
Medium  241 (_+ 62)  328  (.+ 139)  560 (_+ 298)  401 (.+ 537) 
C57BL/6J mice were treated on three consecutive  days with pl 111-139 intranasally  with the doses indicated or with PBS. 1 wk later mice were 
immunized  with Der p 1 in CFA and the periaortic and inguinal  LN were collected  7 d later and cultured in vitro with either  Der p 1 or pl 111-139. 
Data shows the mean response of five mice per group •  SD. 
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Figure 2.  Inhibition of antibody production in vitro. Spleens were re- 
moved from Der p 1 immune mice and the periaortic and inguinal LN 
were collected  from control or tolerized mice who had been immunized 
with Der p  1/CFA. 4  x  10  s spleen or LN cells were cultured alone or 
2  x  10  s spleen cells were mix~ with equal numbers of LN cells from 
either control or tolerized mice. All cells were cultured for 7 d at 37~ 
and supernatants were assayed for Der p  1-specific Abs using an ELISA 
assay. Data show the mean response from five mice per group and is presented 
as ELISA OD units at 405 ran. 
tants of  LN cells from mice tolerized with pl 111-139. When 
LN cells from PBS-treated mice were mixed with immune 
spleen cells, Ab production was unaffected (Fig. 2). How- 
ever, addition of LN cells from pl 111-139-treated mice to 
spleen cell cultures completely inhibited antibody produc- 
tion in vitro (Fig. 2). The mechanisms which lead to inhibi- 
tion of antibody synthesis have all the hallmarks  of being 
classical suppression. That is, not only do tolerized T cells 
fail to provide cognate help to primed B cells in vitro, but 
the tolerized cells also have the capacity to suppress the effector 
function of primed CD4 + Th cells in the spleen. 
Since allergy to HDM reflects a chronic disease, we wished 
to examine whether it were possible to inhibit an on-going 
T cell response using intranasal peptide therapy (16). Mice 
were immunized with Der p 1 in CFA and 10 d later they 
received either 100/~g of pl 111-139 or an irrelevant peptide 
from the Der p 2 allergen, p2 21-35, intranasally on five  con- 
secutive days. After 7 d  the mice were reimmunized with 
Der p 1 in IFA. 1 wk later, LN cells were cultured in vitro 
with the Der p 1 protein and IL-2 production was measured 
in supernatants of 24-h cultures. LN cells from control mice 
treated with the nonimmunogenic peptide  p2 21-35 were 
able to produce IL-2 responses when stimulated with the al- 
lergen in vitro (Fig. 3), whereas IL-2 secretion was completely 
abrogated in LN cells from mice receiving pl 111-139 (Fig. 
3). Equivalent results were obtained if mice were immunized 
with Der p 1/CFA and then 6 mo later received pl 111-139 
on five consecutive days and then were rechallenged with Der 
p 1/IFA 7 d after therapy (Fig. 4). Therefore intranasal pep- 
tide therapy will induce tolerance not only in naive mice but 
also will inhibit the function of T cells previously sensitized 
to the antigen. 
The studies reported here demonstrate that inhalation of 
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Figure  3.  Peptide therapy inhibits ongoing immune responses  to the 
De* p 1 allergen. Mice were treated on five consecutive days with p1111-139 
(O) or a control peptide (m) 10 d after sensitization with Der p 1. 1 wk 
after the completion of therapy mice were reimmunized with Der p 1/IFA 
and LN cells were collected  7 d later.  The data shows the mean II.-2 re- 
sponse of individual mice •  SD. The number of animals per group used 
in each experiment were control (p2 21-35) n  =  5, and tolerized (pl 111-139) 
n  =  10. This experiment has been repeated with over 20 animals with 
equivalent results. 
ance in mice such that they become profoundly  unresponsive 
to a powerful subcutaneous challenge with the antigen. Pep- 
tides containing a dominant T cell epitope were more effec- 
tive tolerogens than those containing only minor epitopes, 
since tolerance could be induced in naive mice with only one 
exposure to pl 111-139, whereas a minimum of three doses 
were required to induce tolerance to a peptide containing a 
minor epitope (pl 156-168) (data not shown). Furthermore, 
10 
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Figure  4.  Inhibition of long-term immune  responses  to  Der  p  1. 
C57BL/6J mice were immunized with 100/~g of Der p  1/CFA i.p. and 
3 wk later mice were reehallenged with 100 t~g of Der p  1/IFA i.p.  6 
mo later, half the mice were given 100 g,g of pl 111-139 intranasally for 
5 d, whereas the other half received p2 21-35 over the same period, and 
1 wk later all mice were immunized with 100 I~g Der p  1/CFA s.c. at 
the base of tail and LN cells were cultured 1 wk later.  Data shows the 
mean II.-2 response of five mice per group  •  SD. 
1786  Peptide-induced T  Cell Tolerance we found that intranasal peptide therapy does inhibit an on- 
going immune response in mice previously sensitized to the 
HDM allergen.  Clearly these results have important  impli- 
cations showing that peptides could be effective immunother- 
apeutic agents in allergic conditions. 
It should be emphasized from these studies that although 
only one peptide epitope was used for treatment,  T  cell re- 
sponses to the other epitopes of the antigen were subsequently 
downregulated. This spreading of tolerance to encompass all 
epitopes of a protein antigen shares  some similarities to the 
model of "infectious" tolerance (21).  However, we cannot 
exclude other regulatory mechanisms operating within the 
lung that may be active in modulating the response antigen- 
reactive T  cells.  There is precedence in the literature  for a 
role of CD8 + T suppressor cells in immunological tolerance 
after inhalation of OVA in rats (13). Therefore, there maybe 
more than  one mechanism  operating  to control T  cell re- 
sponses  to  foreign  antigens  encountered  within  the  nasal 
mucosa and the lung.  Finally,  the HDM response in mice 
provides a promising model for studying further the peptide- 
induced modulation  of allergen-reactive  T  cells. 
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